文献速递胃肠动力与功能性疾病

胃轻瘫及相关疾病患者的大麻素使用:患病率与获益

Cannabinoid Use in Patients With Gastroparesis and Related Disorders: Prevalence and Benefit.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

该研究在2018年6月至9月对学术中心随访的197例有胃轻瘫症状的连续门诊患者进行问卷调查,发现近半数(92例,46.7%)目前或曾经使用大麻素,其中多数感知症状改善;使用大麻素者较未使用者更年轻且胃轻瘫主要症状指数总分更高。

要点

  • 有胃轻瘫症状的门诊患者中46.7%目前或曾经使用大麻素。
  • 使用大麻素者中93.5%用四氢大麻酚、81.3%用大麻二酚、47.2%用屈大麻酚感知症状改善。
  • 使用大麻素者更年轻且胃轻瘫主要症状指数总分更高。

核心结论

  • 有胃轻瘫症状的患者中三分之一正在使用大麻素治疗其慢性症状,其中多数感知症状改善;使用大麻素者更年轻且症状更重。

研究设计与样本

  • 研究为在学术中心随访的连续门诊患者调查,纳入2018年6月至2018年9月有胃轻瘫症状的患者197例,填写症状和当前治疗问卷。

主要发现

  • 197例患者中92例(46.7%)报告目前(35.5%)或过去(11.2%)使用大麻素,包括四氢大麻酚(n=63)、屈大麻酚(n=36)和/或大麻二酚(n=16)。
  • 感知胃轻瘫症状改善的比例:四氢大麻酚93.5%,大麻二酚81.3%,屈大麻酚47.2%。
  • 大麻素最常见使用方式为吸烟(n=46)。
  • 使用大麻素者较无大麻素使用史者更年轻(41.0 ± 15.4岁 vs 48.0 ± 15.9岁;P < 0.01)。
  • 使用大麻素者较无大麻素使用史者胃轻瘫主要症状指数总分更高(3.4 ± 1.0 vs 2.8 ± 1.3;P < 0.01)。

局限性

  • 原文未报告局限性,但结论指出进一步研究大麻素在胃轻瘫中的疗效和安全性将是有用的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Gastroparesis (Gp) can be a challenging disorder to manage due to the paucity of treatment options. We do not know how frequently patients with Gp symptoms resort to cannabinoids to address their symptoms. This study (i) determines the prevalence of cannabinoid use in patients with Gp symptoms, (ii) describes the patients with Gp symptoms using cannabinoids, and (iii) assesses the patients' perceived benefit of cannabinoids for Gp symptoms. METHODS: Consecutive outpatients with symptoms suggestive of Gp seen on follow-up at our academic center from June 2018 to September 2018 filled out questionnaires on their symptoms and the current treatments. RESULTS: Of 197 patients, nearly half (n = 92, 46.7%) reported current (35.5%) or past (11.2%) use of cannabinoids, including tetrahydrocannabinol (n = 63), dronabinol (n = 36), and/or cannabidiol (n = 16). Of these, most perceived improvement in Gp symptoms from cannabinoids (93.5% with tetrahydrocannabinol, 81.3% with cannabidiol, and 47.2% with dronabinol). Cannabinoids were used most commonly via smoking (n = 46). Patients taking cannabinoids were younger (41.0 ± 15.4 vs 48.0 ± 15.9 years; P < 0.01) and had a higher Gastroparesis Cardinal Symptom Index total score (3.4 ± 1.0 vs 2.8 ± 1.3; P < 0.01) compared with patients with no history of cannabinoid use. CONCLUSIONS: A third of patients with Gp symptoms actively use cannabinoids for their chronic symptoms. Most of these patients perceive improvement in their symptoms with cannabinoids. Patients taking cannabinoids were younger and more symptomatic than those not taking cannabinoids. Further studies on the efficacy and safety of cannabinoids in Gp will be useful.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Jehangir A, Parkman HP. Cannabinoid Use in Patients With Gastroparesis and Related Disorders: Prevalence and Benefit. Am J Gastroenterol. 2019. PMID: 30865015. doi:10.14309/ajg.0000000000000181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。